These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 26196596)

  • 1. Genotype-guided dose adjustment for the use of efavirenz in HIV treatment.
    Lam TN; Hui KH; Chan DP; Lee SS
    J Infect; 2015 Nov; 71(5):607-9. PubMed ID: 26196596
    [No Abstract]   [Full Text] [Related]  

  • 2. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
    Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
    J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis.
    Pineda JA; Neukam K; Mallolas J; López-Cortés LF; Cartón JA; Domingo P; Moreno S; Iribarren JA; Clotet B; Crespo M; de Los Santos I; Ortega E; Knobel H; Jiménez-Expósito MJ; Macías J
    J Infect; 2012 Feb; 64(2):204-11. PubMed ID: 22138553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NNRTI hepatotoxicity: efavirenz versus nevirapine.
    Pulido F; Torralba M
    J HIV Ther; 2002 Nov; 7 Suppl 2():S3-16. PubMed ID: 12735215
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis.
    Bickel M; Stephan C; Rottmann C; Carlebach A; Haberl A; Kurowski M; Staszewski S
    Scand J Infect Dis; 2005; 37(6-7):520-2. PubMed ID: 16012018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients.
    Vispo E; Fernández-Montero JV; Labarga P; Barreiro P; Soriano V
    AIDS; 2013 Apr; 27(7):1187-8. PubMed ID: 23739226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching from efavirenz to nevirapine.
    Gelinck LB; Burger DM
    Clin Infect Dis; 2010 Aug; 51(3):365; author reply 365-6. PubMed ID: 20578877
    [No Abstract]   [Full Text] [Related]  

  • 8. Does tenofovir increase efavirenz hepatotoxicity?
    Lattuada E; Lanzafame M; Carolo G; Gottardi M; Concia E; Vento S
    AIDS; 2008 May; 22(8):995. PubMed ID: 18453862
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment can be continued for mild cutaneous reactions associated with efavirenz.
    Isaacs T; Ngwanya RM; Dlamini S; Peter J; Lehloenya R
    J Allergy Clin Immunol Pract; 2019; 7(5):1676-1678. PubMed ID: 30529062
    [No Abstract]   [Full Text] [Related]  

  • 10. Are We Giving Optimal Dose of Efavirenz?
    Yunihastuti E
    Acta Med Indones; 2016 Jan; 48(1):1-2. PubMed ID: 27241537
    [No Abstract]   [Full Text] [Related]  

  • 11. Efavirenz-induced exfoliative dermatitis.
    Zhang JC; Sun YT
    Scand J Infect Dis; 2013 Jan; 45(1):70-2. PubMed ID: 22715849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efavirenz: innocent bystander or direct nephrotoxin?
    Wyatt CM; Rodriguez-Caprio G; Klotman PE
    AIDS; 2007 Jun; 21(10):1393. PubMed ID: 17545729
    [No Abstract]   [Full Text] [Related]  

  • 13. Efavirenz as a cause of ataxia in children.
    Hauptfleisch MP; Moore DP; Rodda JL
    S Afr Med J; 2015 Nov; 105(11):897-8. PubMed ID: 26632310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser.
    Elsharkawy AM; Schwab U; McCarron B; Burt AD; Daly AK; Hudson M; Masson S
    J Clin Virol; 2013 Sep; 58(1):331-3. PubMed ID: 23763943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The challenge of paediatric efavirenz dosing: implications and way forward for the sub-Saharan Africa.
    Mukonzo JK
    AIDS; 2014 Aug; 28(13):1855-7. PubMed ID: 25259700
    [No Abstract]   [Full Text] [Related]  

  • 16. Switching from efavirenz to nevirapine in children: 1-week dose escalation strategy.
    Udomphanit T; Lumbiganon P; Rattanamanee S; Harnlakorn P; Sopharak C; Sringam J; Anutchatchaval S; Tharnprisan P; Kosalaraksa P
    AIDS Res Hum Retroviruses; 2014 Aug; 30(8):727-9. PubMed ID: 24921980
    [No Abstract]   [Full Text] [Related]  

  • 17. Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
    Calza L; Danese I; Colangeli V; Manfredi R; Magistrelli E; Verucchi G; Conti M; Motta R; Viale P
    Infect Dis (Lond); 2015 Sep; 47(9):625-36. PubMed ID: 25875396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two cases of successful efavirenz desensitization in patients with several anti-HIV drugs hypersensitivities.
    D'Erme AM; Severino M; Tiradritti L; Testi S; Tchoimou T; Bertelli A; Zuccati G; Gola M
    G Ital Dermatol Venereol; 2015 Aug; 150(4):476-8. PubMed ID: 26224235
    [No Abstract]   [Full Text] [Related]  

  • 19. The Rise and Fall of Efavirenz.
    Cluck D; Lewis P; Durham SH; Hester EK
    J Int Assoc Provid AIDS Care; 2016 May; 15(3):181-3. PubMed ID: 26858315
    [No Abstract]   [Full Text] [Related]  

  • 20. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz.
    Vitezica ZG; Milpied B; Lonjou C; Borot N; Ledger TN; Lefebvre A; Hovnanian A
    AIDS; 2008 Feb; 22(4):540-1. PubMed ID: 18301070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.